GlobeNewswire: Aastrom Biosciences, Inc. Contains the last 10 of 226 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T07:33:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/11/13/682943/10108002/en/Aastrom-Biosciences-Reports-Third-Quarter-2014-Financial-Results.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences Reports Third-Quarter 2014 Financial Results2014-11-13T13:16:45Z<![CDATA[Conference Call Today at 8:30 a.m. Eastern Time ANN ARBOR, Mich., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended September 30, 2014. The results for the three months ended September 30, 2014 incorporate the first full quarter of operating results following the May 30, 2014 acquisition of Sanofi's cell therapy and regenerative medicine business (the acquired business).]]>https://www.globenewswire.com/news-release/2014/11/05/680299/10106508/en/Aastrom-Biosciences-to-Host-Third-Quarter-2014-Earnings-Call-on-November-13-2014.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 20142014-11-05T21:30:00Z<![CDATA[ANN ARBOR, Mich., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast:]]>https://www.globenewswire.com/news-release/2014/10/09/672111/10102085/en/Aastrom-Biosciences-Announces-Plans-to-Change-Name-to-Vericel-Corporation-and-Move-Headquarters-to-Cambridge-Massachusetts.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts2014-10-09T21:30:00Z<![CDATA[ANN ARBOR, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced plans to change its corporate name to Vericel Corporation and move its corporate headquarters to Cambridge, Massachusetts. The corporate name change is subject to the approval of Aastrom's shareholders. Aastrom will continue to maintain manufacturing facilities in Cambridge, Massachusetts and Ann Arbor, Michigan.]]>https://www.globenewswire.com/news-release/2014/09/17/666633/10098917/en/Aastrom-Biosciences-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares2014-09-17T12:30:00Z<![CDATA[ANN ARBOR, Mich., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the closing of its previously announced underwritten public offering of 15,784,313 shares of its common stock at a price to the public of $2.55 per share, including 2,058,823 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of approximately $40.3 million before deducting underwriting discounts and commissions and other estimated offering expenses.]]>https://www.globenewswire.com/news-release/2014/09/16/666320/10098734/en/Aastrom-Biosciences-to-Present-Three-Year-Data-From-the-SUMMIT-Extension-Study-of-MACI-TM-at-the-2015-American-Academy-of-Orthopedic-Surgeons-Annual-Meeting.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI(TM) at the 2015 American Academy of Orthopedic Surgeons Annual Meeting2014-09-16T12:30:00Z<![CDATA[ANN ARBOR, Mich., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that three-year results from the SUMMIT extension study on the clinical efficacy and safety of matrix-applied characterized autologous chondrocytes (MACI™) for treating cartilage defects will be presented in a poster session at the American Academy of Orthopedic Surgeons annual meeting in Las Vegas, Nevada starting on Tuesday, March 24, 2015. The poster is entitled "SUMMIT Extension: Matrix-induced Autologous Chondrocyte Implant vs Microfracture at 3 Years."]]>https://www.globenewswire.com/news-release/2014/09/11/665334/10098210/en/Aastrom-Biosciences-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences Announces Pricing of Public Offering of Common Stock2014-09-11T12:30:00Z<![CDATA[ANN ARBOR, Mich., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has priced a public offering of 13,725,490 shares of its common stock at a price to the public of $2.55 per share. Aastrom has also granted the underwriters a 30-day option to purchase up to an additional 2,058,823 shares of common stock. The offering is expected to close on or about September 16, 2014, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2014/08/22/660724/10095729/en/Treatment-With-Aastrom-s-Ixmyelocel-T-Shown-to-Reduce-Incidence-of-Major-Adverse-Cardiovascular-Events-in-Patients-With-Ischemic-Dilated-Cardiomyopathy.html?f=22&fvtc=4&fvtv=6690Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy2014-08-22T13:00:00Z<![CDATA[Results From Phase 2a IMPACT-DCM and Catheter-DCM Studies Published in Circulation Research ANN ARBOR, Mich., Aug. 22, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that results from the company's Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) were published in the peer-reviewed journal ]]>https://www.globenewswire.com/news-release/2014/08/14/658668/10094627/en/Aastrom-Biosciences-Reports-Second-Quarter-2014-Financial-Results.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences Reports Second Quarter 2014 Financial Results2014-08-14T11:30:00Z<![CDATA[U.S. Commercial Business Generates Positive Contribution]]>https://www.globenewswire.com/news-release/2014/08/11/657643/10094046/en/Aastrom-Biosciences-to-Host-Second-Quarter-2014-Earnings-Call-on-August-14-2014.html?f=22&fvtc=4&fvtv=6690Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 20142014-08-11T13:30:00Z<![CDATA[ANN ARBOR, Mich., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast:]]>https://www.globenewswire.com/news-release/2014/07/14/650464/10089121/en/Aastrom-Announces-Appointment-of-Zac-Taylor-as-National-Sales-Director.html?f=22&fvtc=4&fvtv=6690Aastrom Announces Appointment of Zac Taylor as National Sales Director2014-07-14T12:30:00Z<![CDATA[Experienced Senior Sales Professional Brings Wealth of Marketing, Strategic Planning and Brand Management Expertise to Aastrom ANN ARBOR, Mich., July 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of Zac Taylor as national sales director.]]>